US EditionADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- On June 2, 2025, in Lausanne, Switzerland, ADC Therapeutics SA awarded stock option grants totaling 107,550 common shares to a pair of recently hired employees.
- The grants were issued as a significant incentive for employment under the Company’s Inducement Plan and received authorization from the Board’s Compensation Committee.
- The Inducement Plan aims to motivate and reward recipients to perform at high levels and vesting occurs over four years subject to continued employment.
- The grants vest 25% on the first anniversary and 1/48th monthly thereafter until full vesting by the fourth anniversary, reflecting reliance on NYSE Rule 303A.08.
- This action reflects ADC Therapeutics’ ongoing efforts to incentivize talent while advancing its commercial-stage pipeline, including FDA-approved ZYNLONTA for lymphoma treatment.
37 Articles
37 Articles
Chatham Star Tribune
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, June 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate…
Cartesian Therapeutics Announces New Employment Inducement Grants
June 03, 2025 07:05 ET | Source: Cartesian Therapeutics, Inc. FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these […] The post Cartesian Therapeutics Announces New Employment Induceme…
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
